Truist Securities Reiterates Buy Rating on Ideaya Biosciences (IDYA): "refined strategy in MTAP net positive"
Tweet Send to a Friend
Truist Securities analyst Greg Renza reiterated a Buy rating and $60.00 price target on Ideaya Biosciences (NASDAQ: IDYA)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
